Haemonetics Appoints Anila Lingamneni as Executive Vice President, Chief Technology Officer, Effective April 1, 2020
March 30, 2020 at 05:15 pm EDT
Share
Haemonetics Corporation announced that it has appointed Anila Lingamneni Executive Vice President and Chief Technology Officer, effective April 1, 2020. She will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. Lingamneni will oversee Haemonetics' s nnovation Agenda and lead the Company's research, development, software,
and medical and clinical affairs. As Chief Technology Officer, she will be responsible for advancing technologies and product investments that support the Company's business units and align with growth strategies including software as a service (SaaS) and digital. Before joining Haemonetics, Lingamneni was Vice President, Renal R&D, at Baxter International, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. In this role, she led a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical product launches. Lingamneni previously served as Vice President, Device Engineering, where she was responsible for all electromechanical devices and software applications for Baxter's medical device portfolio, including infusion systems, compounding systems, renal peritoneal and hemodialysis systems and acute renal therapy systems.
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Companyâs Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Companyâs Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.